A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Saul Priceman, PhD
Advertisement
Articles by Saul Priceman, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC
2
ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care
3
EMD Associated With Poorer Outcomes in Previously Treated R/R Multiple Myeloma
4
Kamdar Names Potential Treatment Options Beyond Liso-cel in R/R LBCL
5
